Securities Lawsuit Filed Against Alto Neuroscience, Inc.

Strategic Insights -

Alto Neuroscience, Inc. (NYSE: ANRO) faced a securities lawsuit following allegations that the company made false statements and concealed the ineffectiveness of its product, ALTO-100, in treating major depressive disorder. The lawsuit focuses on the initial public offering (IPO) conducted on February 2, 2024, and the subsequent stock purchases between February 2, 2024, and October 22, 2024. The complaint alleges that Alto's public statements were materially false and misleading during this time, overstating the company's business and financial prospects.

Key Takeaways:

  • The lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Alto common stock from the IPO documents in connection with the Company's initial public offering conducted on February 2, 2024, and/or from February 2, 2024, to October 22, 2024.
  • The complaint alleges that Alto made false statements and/or concealed that ALTO-100's clinical, regulatory, and commercial prospects were overstated.
  • Alto's public statements were allegedly materially false and misleading due to the ineffectiveness of ALTO-100 in treating major depressive disorder.
  • Initially, a total of $15 million was raised in the IPO for Alto, which included a cash balance of $12.6 million and $2.4 million in convertible notes.
  • The shareholders' class include all those who purchased or acquired Alto common stock and securities between February 2, 2024, and October 22, 2024.
  • The lawsuit is being led by Levi & Korsinsky, LLP, a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders.
  • Levi & Korsinsky has been ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven consecutive years.

Statistics:

  • The lawsuit covers stock purchases from February 2, 2024, to October 22, 2024.
  • Alto's initial public offering raised $15 million, which included $12.6 million in cash and $2.4 million in convertible notes.
  • The IPO was conducted on February 2, 2024.
  • The lawsuit alleges that Alto's product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe.

Sources:

  • Press release by Newsfile Corp. (September 12, 2025)
  • https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=167037&wire=5&utm_campaign=28
  • Levi & Korsinsky, LLP (Joseph E. Levi, Esq., and Ed Korsinsky, Esq.)